{"id":"ibritumomab-tiuxetan-zevalin","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Thrombocytopenia"},{"rate":"25-50","effect":"Neutropenia"},{"rate":"10-25","effect":"Anemia"},{"rate":"10-20","effect":"Infusion reactions"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Nausea"},{"rate":null,"effect":"Secondary malignancies"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of a murine anti-CD20 monoclonal antibody conjugated to a chelator that carries yttrium-90, a beta-emitting radioisotope. Upon binding to CD20-expressing B lymphoma cells, the antibody delivers high-energy radiation directly to the malignant cells, causing DNA damage and cell death. This radioimmunotherapy approach combines the targeting specificity of monoclonal antibodies with the cytotoxic power of radiation.","oneSentence":"Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that binds to CD20 on B cells and delivers yttrium-90 radiation directly to tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:13.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma"},{"name":"Previously untreated follicular lymphoma (in combination with rituximab)"}]},"trialDetails":[{"nctId":"NCT00690560","phase":"PHASE2","title":"Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-05","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT02320292","phase":"PHASE3","title":"Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-02-11","conditions":"Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma","enrollment":20},{"nctId":"NCT01359592","phase":"PHASE2","title":"S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2011-09","conditions":"Lymphoma","enrollment":159},{"nctId":"NCT00577278","phase":"PHASE2","title":"A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-10-03","conditions":"Graft Versus Host Disease, Leukemia, Lymphoma","enrollment":41},{"nctId":"NCT00031642","phase":"PHASE1, PHASE2","title":"Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-01-01","conditions":"Lymphoma","enrollment":26},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT00168727","phase":"PHASE4","title":"Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Biogen","startDate":"2003-06-01","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade","enrollment":12},{"nctId":"NCT01811368","phase":"PHASE2","title":"Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Joseph Tuscano","startDate":"2013-03-12","conditions":"Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT00493467","phase":"PHASE2","title":"Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-06","conditions":"Lymphoma","enrollment":31},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":"Follicular Non-Hodgkin's Lymphoma","enrollment":807},{"nctId":"NCT00290511","phase":"PHASE2","title":"Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-06-29","conditions":"Lymphoma","enrollment":49},{"nctId":"NCT00322218","phase":"PHASE3","title":"Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-05","conditions":"Lymphoma, Large Cell, Diffuse","enrollment":68},{"nctId":"NCT00384111","phase":"PHASE3","title":"Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-10","conditions":"Follicular Lymphoma, Lymphoma, Follicular","enrollment":26},{"nctId":"NCT00070018","phase":"PHASE2","title":"S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2004-02","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT00637832","phase":"PHASE2","title":"Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"University of Southampton","startDate":"2008-04-01","conditions":"Lymphoma","enrollment":1},{"nctId":"NCT01510184","phase":"PHASE3","title":"Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-04-19","conditions":"Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma","enrollment":79},{"nctId":"NCT01662102","phase":"PHASE3","title":"Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2012-12-11","conditions":"Follicular Lymphoma","enrollment":1},{"nctId":"NCT01549886","phase":"PHASE2","title":"Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2011-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":5},{"nctId":"NCT01448928","phase":"","title":"Zevalin Post-marketing Surveillance in Japan","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2008-09","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":400},{"nctId":"NCT01434472","phase":"PHASE2","title":"High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11-16","conditions":"Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT00562978","phase":"PHASE1, PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-05-16","conditions":"Lymphoma","enrollment":54},{"nctId":"NCT01234766","phase":"PHASE2","title":"Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2010-10","conditions":"Lymphoma, Follicular","enrollment":39},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":"Diffuse Large Cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT00058422","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-02-10","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT00491491","phase":"PHASE3","title":"Zevalin-beam for Aggressive Lymphoma","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2007-06","conditions":"Non-Hodgkin's Lymphoma","enrollment":60},{"nctId":"NCT01973062","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-03","conditions":"Primary Central Nervous System Non-Hodgkin Lymphoma","enrollment":1},{"nctId":"NCT00889798","phase":"","title":"Tumor Registry of Lymphatic Neoplasia","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2009-04","conditions":"Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)","enrollment":3795},{"nctId":"NCT01490723","phase":"PHASE2","title":"Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-01","conditions":"Leukemia, Lymphoma","enrollment":20},{"nctId":"NCT00662948","phase":"PHASE2","title":"ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2008-12","conditions":"Lymphoma","enrollment":149},{"nctId":"NCT00582166","phase":"PHASE2","title":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2005-01-25","conditions":"Non-Hodgkin's Lymphoma","enrollment":18},{"nctId":"NCT01493479","phase":"PHASE2","title":"Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2007-06-06","conditions":"Follicular Lymphoma","enrollment":76},{"nctId":"NCT00372905","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2007-07-24","conditions":"Lymphoma","enrollment":18},{"nctId":"NCT00732498","phase":"PHASE2","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2006-05-15","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT00089284","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-10-28","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":30},{"nctId":"NCT00392691","phase":"PHASE1","title":"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-10","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT01686165","phase":"PHASE2","title":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2012-08-31","conditions":"Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":5},{"nctId":"NCT00416312","phase":"","title":"Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-07","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00012298","phase":"PHASE1, PHASE2","title":"Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT00695409","phase":"PHASE2","title":"Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-18","conditions":"Lymphoma","enrollment":122},{"nctId":"NCT00119392","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2004-06","conditions":"B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma","enrollment":42},{"nctId":"NCT00477815","phase":"PHASE1","title":"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-05-31","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":30},{"nctId":"NCT02366663","phase":"PHASE3","title":"BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2015-01","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT00689169","phase":"PHASE2","title":"Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2007-08","conditions":"Lymphoma, Large Cell, Diffuse","enrollment":75},{"nctId":"NCT00073957","phase":"PHASE2","title":"Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2003-12","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT00110149","phase":"PHASE2","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2004-05","conditions":"Lymphoma","enrollment":12},{"nctId":"NCT00088881","phase":"PHASE2","title":"Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-12","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma","enrollment":62},{"nctId":"NCT00644371","phase":"PHASE2","title":"Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2007-11","conditions":"Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT01207765","phase":"PHASE2","title":"Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma","status":"TERMINATED","sponsor":"Tufts Medical Center","startDate":"2008-04","conditions":"Multiple Myeloma","enrollment":8},{"nctId":"NCT00334438","phase":"PHASE1","title":"Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-07","conditions":"Lymphoma","enrollment":12},{"nctId":"NCT02992223","phase":"","title":"Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT","status":"COMPLETED","sponsor":"A.O.U. Città della Salute e della Scienza","startDate":"2014-07","conditions":"Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":58},{"nctId":"NCT00607854","phase":"PHASE2","title":"Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2008-02","conditions":"Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":31},{"nctId":"NCT00062114","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-04","conditions":"Lymphoma","enrollment":84},{"nctId":"NCT01446562","phase":"PHASE2","title":"Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2007-05","conditions":"Follicular Lymphoma","enrollment":34},{"nctId":"NCT00761384","phase":"PHASE1, PHASE2","title":"High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2008-04","conditions":"B-cell Lymphoma","enrollment":7},{"nctId":"NCT00336843","phase":"PHASE2","title":"Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2005-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":19},{"nctId":"NCT00414089","phase":"PHASE2","title":"Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL","status":"WITHDRAWN","sponsor":"AHS Cancer Control Alberta","startDate":"","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00646750","phase":"PHASE2","title":"Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2008-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT00438880","phase":"PHASE1, PHASE2","title":"Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2004-10","conditions":"Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma","enrollment":38},{"nctId":"NCT00310128","phase":"PHASE2","title":"Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma","status":"WITHDRAWN","sponsor":"AIDS Malignancy Consortium","startDate":"2006-02","conditions":"AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma","enrollment":""},{"nctId":"NCT00453102","phase":"PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2006-02","conditions":"Marginal Zone Lymphoma","enrollment":18},{"nctId":"NCT00005592","phase":"PHASE2","title":"Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"1999-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT01497275","phase":"PHASE2","title":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2012-02","conditions":"Mantle-Cell Lymphoma","enrollment":5},{"nctId":"NCT00319332","phase":"PHASE3","title":"A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular, Lymphoma, Follicular","enrollment":""},{"nctId":"NCT00440583","phase":"PHASE2","title":"The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2006-09","conditions":"Diffuse Large B-cell Lymphoma","enrollment":15},{"nctId":"NCT00220285","phase":"PHASE2","title":"Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-08","conditions":"Non-Hodgkin's Lymphoma, Lymphoma, B-Cell, Lymphoma, Low-Grade","enrollment":45},{"nctId":"NCT01538472","phase":"PHASE1, PHASE2","title":"Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT00302757","phase":"PHASE1, PHASE2","title":"Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2006-03","conditions":"Non-Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT01130194","phase":"PHASE2","title":"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2006-07","conditions":"Follicular Lymphoma","enrollment":29},{"nctId":"NCT00119730","phase":"PHASE2","title":"Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-02","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT00070447","phase":"PHASE2","title":"Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-11","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00033423","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2001-08","conditions":"Lymphoma","enrollment":18},{"nctId":"NCT00387023","phase":"NA","title":"Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-02","conditions":"Non-Hodgkin's Lymphoma, Lymphoma","enrollment":12},{"nctId":"NCT00048737","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-10","conditions":"Lymphoma, Leukemia","enrollment":70},{"nctId":"NCT00493454","phase":"PHASE2","title":"Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-04","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT00521560","phase":"PHASE2","title":"A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH","startDate":"2006-03","conditions":"Primary Non-Hodgkin-Lymphoma, Refractory Non-Hodgkin-Lymphoma, CD20+ Aggressive Non-Hodgkin's Lymphoma","enrollment":28},{"nctId":"NCT00064246","phase":"PHASE1, PHASE2","title":"Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-07","conditions":"Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":28},{"nctId":"NCT00036855","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":"AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder","enrollment":36},{"nctId":"NCT00082836","phase":"NA","title":"Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2004-12","conditions":"Lymphoma","enrollment":10},{"nctId":"NCT00017381","phase":"EARLY_PHASE1","title":"Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma","enrollment":30},{"nctId":"NCT00060294","phase":"PHASE1","title":"Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2003-04","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00902525","phase":"PHASE2","title":"Zevalin Twice in Aggressive Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie","startDate":"2008-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":25},{"nctId":"NCT00397800","phase":"PHASE1, PHASE2","title":"Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Technical University of Munich","startDate":"2005-06","conditions":"Lymphoma","enrollment":12},{"nctId":"NCT00772655","phase":"PHASE2","title":"Zevalin® First Line in Follicular Lymphoma","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":"Follicular Lymphoma","enrollment":60},{"nctId":"NCT00463463","phase":"PHASE3","title":"Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"2007-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":""},{"nctId":"NCT00186589","phase":"PHASE1","title":"90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL","status":"COMPLETED","sponsor":"Stanford University","startDate":"2004-05","conditions":"Lymphoma, Non-Hodgkin, Blood and Marrow Transplant (BMT)","enrollment":30},{"nctId":"NCT00058292","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2000-04","conditions":"Lymphoma","enrollment":44},{"nctId":"NCT00514475","phase":"PHASE2","title":"Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2005-11","conditions":"Mantle Cell Lymphoma","enrollment":160},{"nctId":"NCT00505232","phase":"PHASE2","title":"Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)","status":"COMPLETED","sponsor":"CABYC","startDate":"2006-01","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT01479387","phase":"","title":"Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-08","conditions":"Non-Hodgkin's Lymphoma (NHL)","enrollment":72},{"nctId":"NCT00038623","phase":"PHASE2","title":"Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-04","conditions":"Lymphoma, Mantle-Cell","enrollment":35},{"nctId":"NCT00193505","phase":"PHASE2","title":"Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2003-10","conditions":"Non-Hodgkins Lymphoma","enrollment":40},{"nctId":"NCT00193440","phase":"PHASE2","title":"Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2002-04","conditions":"Non-Hodgkins Lymphoma","enrollment":40},{"nctId":"NCT00271050","phase":"PHASE1","title":"External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2005-12","conditions":"Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT00386321","phase":"PHASE2","title":"Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Chulalongkorn University","startDate":"2006-04","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT01164696","phase":"","title":"A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Lymphoma, Follicular, Non-Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT01157988","phase":"PHASE2","title":"90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2007-01","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":20},{"nctId":"NCT00354822","phase":"PHASE2","title":"Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.","status":"TERMINATED","sponsor":"A.O. Ospedale Papa Giovanni XXIII","startDate":"2005-08","conditions":"Lymphoma, Non-Hodgkin","enrollment":25},{"nctId":"NCT00859001","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":"Follicular Lymphoma","enrollment":55},{"nctId":"NCT00850512","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ibritumomab","Zevalin","IDEC-Y2B8","Rituximab (Mabthera)"],"phase":"marketed","status":"active","brandName":"Ibritumomab Tiuxetan (Zevalin)","genericName":"Ibritumomab Tiuxetan (Zevalin)","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that binds to CD20 on B cells and delivers yttrium-90 radiation directly to tumor cells. Used for Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma, Previously untreated follicular lymphoma (in combination with rituximab).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}